8-K Announcements
6Material company update
May 7, 2026·SEC
Material company update
Mar 5, 2026·SEC
Material company update
Feb 5, 2026·SEC
Shattuck Labs, Inc.(STTK)Earnings, Financials & Key Ratios
STTK•NASDAQ
$6.51
Price updated Jul 6, 2026
AboutShattuck Labs, Inc., a clinical-stage biotechnology company, develops therapeutics for the treatment of cancer and autoimmune disease in the United States. The company's lead product candidate is SL-172154, which is in Phase 1 clinical trial for the treatment of ovarian, fallopian tube, and peritoneal cancers. It also develops SL-279252 that is in Phase 1 clinical trial in patients with advanced solid tumors and lymphoma. The company was incorporated in 2016 and is headquartered in Austin, Texas.Show more
- Revenue$1M-82.5%
- EBITDA-$48M+37.7%
- Net Income-$49M+35.3%
- EPS (Diluted)-0.70+53.0%
- Gross Margin100%
- EBITDA Margin-4782%-256.5%
- Operating Margin-5150.8%-265.8%
- Net Margin-4880.9%-270.3%
- ROE-60.25%+10.4%
STTK Price & Volume
Shattuck Labs, Inc. (STTK) stock price & volume — 10-year historical chart
Loading chart...
STTK Growth Metrics
Shattuck Labs, Inc. (STTK) revenue, earnings & EPS growth — 3, 5 & 10-year CAGR
Revenue CAGR
10 Years-
5 Years-36.82%
3 Years15.32%
TTM-78.29%
Profit CAGR
10 Years-
5 Years-
3 Years-
TTM29.36%
EPS CAGR
10 Years-
5 Years-
3 Years-
TTM54.68%
Return on Capital
10 Years-43.93%
5 Years-49.68%
3 Years-62.66%
Last Year-62.02%
STTK Recent Earnings
Shattuck Labs, Inc. (STTK) EPS & revenue vs analyst estimates — last 4 quarters
●Beat EPS 9/12 qtrs (75%)●Beat Revenue 8/12 qtrs (100%)
Q2 2026Latest
May 7, 2026Metric
Actual
Est
EPS
$0.13+7.1%
$0.14
Rev
—
—
Q2 2026
Mar 5, 2026Metric
Actual
Est
EPS
$0.12+0.0%
$0.12
Rev
—
$250,000
Q4 2025
Nov 6, 2025Metric
Actual
Est
EPS
$0.14+6.7%
$0.15
Rev
$1M+500.0%
$166,670
Q3 2025
Aug 14, 2025Metric
Actual
Est
EPS
$0.24+4.0%
$0.25
Rev
—
—
| Quarter | Date | EPS (Act vs Est) | Revenue (Act vs Est) |
|---|---|---|---|
| Q2 2026Latest | May 7, 2026 | $0.13vs $0.14+7.1% | — |
| Q2 2026 | Mar 5, 2026 | $0.12vs $0.12+0.0% | —vs $250,000 |
| Q4 2025 | Nov 6, 2025 | $0.14vs $0.15+6.7% | $1Mvs $166,670+500.0% |
| Q3 2025 | Aug 14, 2025 | $0.24vs $0.25+4.0% | — |
Based on last 12 quarters of dataView full earnings history →
Peers Comparison
Key metrics vs top competitors for Shattuck Labs, Inc. (STTK)
| Company | Price | Market Cap | P/E Ratio | Rev Growth (1Y) | Net Margin | ROE | Div Yield |
|---|---|---|---|---|---|---|---|
| $6.51 | $311.85M | -9.30 | -82.52% | -4880.9% | -60.25% | — | |
| $29.98 | $3.02B | -9.11 | -4.26% | -156.36% | -68.97% | — | |
| $38.60 | $7.92B | -13.94 | — | — | -68.16% | — | |
| $3.41 | $142M | -1002.94 | 10.37% | 52.16% | — | — | |
| $3.30 | $236.1M | -2.34 | — | — | -30.9% | — | |
| $5.94 | $11.58M | -0.51 | -13.43% | -299.66% | — | — |
Compare STTK vs Peers
Shattuck Labs, Inc. (STTK) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.
STTK SEC Filings & Documents
Shattuck Labs, Inc. (STTK) SEC filings — annual & quarterly reports (10-K, 10-Q)
Get notified when STTK posts new earnings or crosses analyst targets
Free. No account needed. Unsubscribe any time.
STTK Frequently Asked Questions
Shattuck Labs, Inc. (STTK) stock FAQ — growth, dividends, profitability & financials explained
Growth & Financials
What is Shattuck Labs, Inc.'s revenue?
Shattuck Labs, Inc. (STTK) reported $1.0M in revenue for fiscal year 2025. This represents a 96% decrease from $22.4M in 2018.
How fast is Shattuck Labs, Inc. growing?
Shattuck Labs, Inc. (STTK) saw revenue decline by 82.5% over the past year.
Is STTK profitable?
Shattuck Labs, Inc. (STTK) reported a net loss of $49.9M for fiscal year 2025.
Dividend & Returns
What is STTK's return on equity?
Shattuck Labs, Inc. (STTK) has a return on equity (ROE) of -60.3%. Negative ROE indicates the company is unprofitable.
What is Shattuck Labs, Inc.'s free cash flow?
Shattuck Labs, Inc. (STTK) had negative free cash flow of $41.3M in fiscal year 2025, likely due to heavy capital investments.